News | May 01, 2024
Lilly posts Q1 2024 revenue up 26% at US$ 8.77 billion
2024 full-year revenue guidance raised by US$ 2 billion
2024 full-year revenue guidance raised by US$ 2 billion
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Sales reflect continued strong growth in oncology and vaccines
Approval from Colombia's INVIMA will accelerate growth in Colombia, by registering our product and getting regular supplies
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Longest survival follow-up ever reported for immunotherapy treatment in this setting
ABRYSVO met its trial primary endpoints in adults aged 18 to 59 with an increased respiratory syncytial virus (RSV) disease risk.
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated
